Evidence map›Paper›PMID 32042330›Full record

ArticleTheranostics2020

Sex Differences Revealed in a Mouse CFA Inflammation Model with Macrophage Targeted Nanotheranostics.

Lu Liu, Huseyin Karagoz, Michele Herneisey, Fatih Zor, Takaaki Komatsu, Shannon Loftus, Bratislav M Janjic, Vijay S Gorantla, Jelena M Janjic

Open access · goldAbstract read
In one paragraph

Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Anti-Inflammatory Potential ofMicroorganisms · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Lu LiuGraduate School of Pharmaceutical Sciences, School of Pharmacy, Duquesne University, Pittsburgh, PA, USA.
Huseyin KaragozDepartment of Surgery, Institute of Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States.
Michele HerneiseyGraduate School of Pharmaceutical Sciences, School of Pharmacy, Duquesne University, Pittsburgh, PA, USA.
Fatih ZorDepartment of Surgery, Institute of Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States.
Takaaki KomatsuDepartment of Pharmacology, Daiichi University of Pharmacy, Fukuoka, Japan.
Shannon LoftusGraduate School of Pharmaceutical Sciences, School of Pharmacy, Duquesne University, Pittsburgh, PA, USA.
Bratislav M JanjicNRG Oncology Foundation Inc., University of Pittsburgh, Pittsburgh PA, United States.
Vijay S GorantlaDepartment of Surgery, Institute of Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States.
Jelena M JanjicGraduate School of Pharmaceutical Sciences, School of Pharmacy, Duquesne University, Pittsburgh, PA, USA.
Duquesne University · USDaiichi University of Pharmacy · JP

Funding

Theranostic Pain Nanomedicines: imaging inflammation, reducing pain and need for opioidsR21DA039621 · NIDA · DUQUESNE UNIVERSITY · PI JANJIC, JELENA M · 2015 to 2016
$328k
NIDA NIH HHS R21 DA039621
6 · The paper itself

Abstract

Monocyte derived macrophages (MDMs) infiltrate sites of infection or injury and upregulate cyclooxygenase-2 (COX-2), an enzyme that stimulates prostaglandin-E2 (PgE2). Nanotheranostics combine therapeutic and diagnostic agents into a single nanosystem. In previous studies, we demonstrated that a nanotheranostic strategy, based on theranostic nanoemulsions (NE) loaded with a COX-2 inhibitor (celecoxib, CXB) and equipped with near-infrared fluorescent (NIRF) reporters, can specifically target circulating monocytes and MDMs. The anti-inflammatory and anti-nociceptive effects of such cell-specific COX-2 inhibition lasted several days following Complete Freund's Adjuvant (CFA) or nerve injury in male mice. The overall goal of this study was to investigate the extended (up to 40 days) impact of MDM-targeted COX-2 inhibition and any sex-based differences in treatment response; both of which remain unknown. Our study also evaluates the feasibility and efficacy of a preclinical nanotheranostic strategy for mechanistic investigation of the impact of such sex differences on clinical outcomes.

Indexed as

Adjuvants, ImmunologicAdministration, IntravenousAnimalsCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsDinoprostoneDisease Models, AnimalDrug Delivery SystemsFeasibility StudiesFemaleFreund's AdjuvantInflammationMacrophagesMaleMiceAdjuvants, ImmunologicCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsDinoprostoneFreund's Adjuvantinflammatory painmacrophagesnanotheranostic.Pain nanomedicinesex differences

Identifiers

PMID32042330
PMCPMC6993234
OpenAlexW2998017120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.